Haematological malignancies are a diverse group of cancers that begin in the blood, bone marrow, or lymph nodes, affecting the production and function of blood cells that keep our bodies healthy. Understanding these diseases helps patients and families navigate diagnosis, treatment, and life beyond cancer.

What Are Haematological Malignancies?

Haematological malignancies, also called blood cancers, are diseases where abnormal blood cells grow out of control. These cancers develop in the places where blood is made and stored—primarily in the bone marrow, which is the soft, spongy tissue inside our bones where blood cells are produced. Unlike cancers that form solid tumors in organs, haematological malignancies involve cells that flow through the bloodstream and lymphatic system, which is why they are sometimes called liquid tumors.^[3][7]

When someone develops a haematological malignancy, the normal process of blood cell development goes wrong. The bone marrow contains stem cells that normally mature into three types of blood cells: red blood cells that carry oxygen, white blood cells that fight infections, and platelets that help blood clot. In blood cancers, this orderly development is interrupted by uncontrolled growth of abnormal cells. These cancerous cells prevent the blood from doing its essential jobs, like protecting the body from infections or stopping bleeding when you get a cut.^[3]

The term “haematological malignancies” covers many different diseases. They are traditionally grouped by where the cancer is first found: leukemias start in the blood, lymphomas begin in the lymph nodes, and myelomas develop in the bone marrow. However, modern medicine now classifies these cancers more precisely based on the specific type of cell that becomes cancerous, the genetic changes in those cells, and how the disease behaves. This more detailed classification recognizes over 100 different subtypes, each with its own characteristics and treatment needs.^[6][7]

The Three Main Categories

Haematological malignancies fall into three broad families, each affecting different parts of the blood and immune system. Understanding these categories helps patients grasp what is happening in their bodies.

Leukemia is a cancer that affects white blood cells. In this disease, the bone marrow produces too many abnormal white blood cells too quickly. These defective cells cannot fight infections properly, and their rapid multiplication crowds out healthy cells, leaving less room for normal red blood cells and platelets to develop. Leukemia can be acute, meaning it develops quickly and needs immediate treatment, or chronic, developing more slowly over months or years. The high number of abnormal cells may also cause very high white blood cell counts that can lead to serious complications.^[3][2]

Lymphoma is a cancer of the lymphatic system, which is the network of vessels, tissues, and organs that removes excess fluid from the body and produces immune cells. Lymphoma develops when a type of white blood cell called a lymphocyte becomes abnormal and multiplies uncontrollably. These cancerous lymphocytes gather in lymph nodes and other tissues, forming masses. Over time, they damage the immune system’s ability to protect the body. Lymphomas are divided into two main types: Hodgkin lymphoma and non-Hodgkin lymphoma, which differ in the specific cells involved and how they behave.^[3]

Myeloma, often called multiple myeloma, is a cancer of plasma cells. Plasma cells are specialized white blood cells that normally produce antibodies—the proteins that help fight diseases and infections. When someone has myeloma, abnormal plasma cells multiply in the bone marrow and prevent the production of normal antibodies. This leaves the immune system weakened and unable to defend against infections effectively. The cancerous plasma cells can also cause damage to bones and other organs.^[3]

How Common Are Haematological Malignancies?

Haematological malignancies are among the most common cancers worldwide, representing the fifth most common cancer group in economically developed regions. These diseases affect hundreds of thousands of people every year. In 2019, there were approximately 1,343,850 new cases of haematological malignancies diagnosed globally. This number has been increasing since 1990, reflecting both growing populations and improved detection methods.^[4][6]

In the United States, the distribution of haematological malignancies shows interesting patterns. Lymphomas make up the largest share, accounting for about 55.6 percent of all cases. Among lymphomas, non-Hodgkin’s lymphomas are much more common than Hodgkin’s lymphomas, representing 48.6 percent compared to 7.0 percent of all haematological malignancies. Leukemias account for approximately 30.4 percent of cases, while myelomas represent about 14.0 percent of the total.^[7]

The burden of haematological malignancies is generally higher in men than in women. Studies tracking disease patterns show that males experience higher rates of most blood cancers, though the reasons for this difference are not fully understood. Age also plays an important role—many haematological malignancies become more common as people get older, with risk increasing significantly after age 50. However, some types, particularly certain leukemias, can affect children and young adults.^[4]

What Causes Haematological Malignancies?

The exact causes of most haematological malignancies remain incompletely understood. These cancers develop when something goes wrong with the genetic material inside blood cells, causing them to grow and multiply abnormally. Unlike many solid tumors where specific environmental causes can be identified, blood cancers often arise from complex interactions between a person’s genes and various factors they may encounter during their lifetime.

Chromosomal translocations are a particularly important cause of haematological malignancies. These are unusual events where pieces of different chromosomes break off and swap places with each other. This rearrangement creates abnormal genes that can cause cells to become cancerous. While chromosomal translocations are uncommon in solid tumors, they are a very common cause of blood cancers. For example, chronic myeloid leukemia is defined by a specific translocation between chromosomes 9 and 22 that creates an abnormal chromosome called the Philadelphia chromosome.^[2][7]

Some haematological malignancies develop after exposure to certain cancer treatments. Radiation therapy or chemotherapy given for a previous cancer can sometimes damage the bone marrow in ways that lead to acute myeloid leukemia years later. This is called secondary or treatment-related leukemia. Similarly, some blood cancers can evolve from other blood disorders. Myeloproliferative disorders, where the bone marrow makes too many of certain blood cells, can sometimes transform into acute leukemia over time.^[2]

The specific cause varies by the type of haematological malignancy. Acute myeloid leukemia may occur without any identifiable cause, or it may develop secondary to chemotherapy, radiation, or transformation from other bone marrow conditions. The development of disease reflects disruption of the normal process by which blood cells are made, though the initial trigger for this disruption often cannot be pinpointed.^[2]

Who Is at Risk?

While anyone can develop a haematological malignancy, certain factors increase the likelihood of these diseases. Understanding risk factors does not mean someone will definitely develop cancer, but it helps identify who might benefit from increased awareness or monitoring.

Age is one of the strongest risk factors for many haematological malignancies. As people grow older, their risk increases significantly. Many blood cancers have median diagnostic ages in the 60s and 70s. For instance, chronic lymphocytic leukemia typically occurs at a median age of 72 years. However, age affects different blood cancers differently—acute promyelocytic leukemia has a median diagnostic age of only 50 years, demonstrating that younger adults can also be affected.^[2]

Gender plays a role in risk, with males experiencing higher rates of most haematological malignancies compared to females. Chronic lymphocytic leukemia, for example, is twice as likely to occur in men than women. The reasons for these gender differences are not fully understood but may involve hormonal factors, genetic differences, or varying exposures to environmental risks throughout life.^[2]

Previous cancer treatment creates elevated risk. People who have received radiation therapy or certain types of chemotherapy for other cancers face increased likelihood of developing treatment-related blood cancers, particularly acute myeloid leukemia. This risk typically emerges years after the original treatment. Pre-existing blood disorders also increase risk, as conditions like myelodysplastic syndrome can progress to acute leukemia.^[2]

Geographic and economic factors influence risk patterns. The burden of haematological malignancies varies by region and country, with differences related to economic development, healthcare access, environmental exposures, and population genetics. These variations show that both biological and social factors contribute to who develops these diseases.^[4]

Recognizing the Symptoms

The symptoms of haematological malignancies can be subtle at first and often resemble common, less serious illnesses. This similarity can make early detection challenging. However, recognizing patterns of symptoms that persist or worsen is important for seeking timely medical evaluation.

Many people with blood cancers experience persistent fatigue that does not improve with rest. This overwhelming tiredness occurs because the cancer interferes with the production of healthy red blood cells, leading to anemia, a condition where the blood cannot carry enough oxygen to meet the body’s needs. The fatigue can be so severe that it affects daily activities and quality of life.^[10]

Frequent infections are another common sign. Because haematological malignancies affect white blood cells that fight disease, people with blood cancers may get infections more often than usual or find that infections are harder to shake off. These might include repeated respiratory infections, fevers without obvious cause, or infections that respond poorly to standard treatments.^[2][10]

Bleeding and bruising problems can occur when blood cancers reduce platelet production. Platelets are the tiny cell fragments that help blood clot. Without enough platelets, people may bruise easily from minor bumps, develop small red spots on the skin, experience nosebleeds, or have bleeding gums. Women might notice heavier or prolonged menstrual periods. These bleeding issues happen because the bone marrow is too busy making cancer cells to produce adequate platelets.^[2][10]

Constitutional symptoms affect many patients with haematological malignancies. These include unintentional weight loss, where people lose weight without trying or changing their diet. Night sweats can be so severe that people wake up drenched and need to change their clothing or bedding. Fever may come and go without an obvious infection. These symptoms reflect the body’s response to cancer and the metabolic changes it causes.^[2][10]

Swollen lymph nodes, particularly in the neck, armpits, or groin, may appear as painless lumps. These swellings occur when cancer cells accumulate in the lymph nodes. In lymphomas, this is often one of the first noticeable signs. Abdominal pain or feeling full quickly when eating can happen when the spleen or liver becomes enlarged from cancer cell buildup.^[2][10]

Shortness of breath, headaches, and joint pain may occur depending on the specific type and location of the blood cancer. Some patients experience itchy skin without a rash. Nausea and loss of appetite can make eating difficult. The combination and severity of symptoms vary considerably between different haematological malignancies and between individual patients.^[2][10]

Prevention and Early Detection

Unlike some cancers where clear prevention strategies exist, preventing haematological malignancies is challenging because the causes are often unknown. However, certain approaches may help reduce risk or detect problems early when they are most treatable.

For people who have received cancer treatment in the past, regular follow-up with healthcare providers is important. Survivors of cancer who received chemotherapy or radiation therapy should be aware of their increased risk for secondary blood cancers and maintain appropriate monitoring. Healthcare providers can watch for early signs of bone marrow problems through routine blood tests during survivorship care.^[2]

Maintaining overall health through good lifestyle habits supports the immune system and bone marrow function. While specific dietary or exercise interventions have not been proven to prevent haematological malignancies, general wellness practices contribute to better health outcomes. Some studies have explored whether cancer survivors who adopt healthier lifestyles after diagnosis experience better outcomes, though research in this area for blood cancers specifically is limited.^[21]

Awareness of warning signs allows for earlier medical evaluation. People experiencing persistent symptoms—such as unexplained fatigue that lasts weeks, repeated infections, unusual bleeding or bruising, or unexplained weight loss—should discuss these concerns with their healthcare provider. While these symptoms often have benign causes, persistent or worsening symptoms warrant medical assessment.

For individuals with known precursor conditions, closer monitoring may be appropriate. Certain conditions recognized as potentially pre-malignant, such as monoclonal B-cell lymphocytosis or monoclonal gammopathy of undetermined significance, may be monitored by healthcare providers. While these conditions do not always progress to cancer, awareness allows for early detection if transformation occurs.^[6]

How Haematological Malignancies Affect the Body

Understanding the physical changes that occur in haematological malignancies helps explain both the symptoms patients experience and the treatments they need. These cancers fundamentally disrupt the normal way blood cells are made and function.

The bone marrow is normally a highly organized factory for blood cell production. Stem cells in the bone marrow follow a carefully controlled process of division and maturation to become the different types of blood cells the body needs. In haematological malignancies, this orderly process breaks down. Cancer cells multiply rapidly and chaotically, taking over space in the bone marrow and interfering with normal cell production. This leads to bone marrow failure, where the bone marrow cannot make enough healthy blood cells.^[2]

Pancytopenia is a common result of bone marrow failure. This medical term describes low counts of all three major blood cell types: red blood cells, white blood cells, and platelets. However, paradoxically, some haematological malignancies can cause very high white blood cell counts because the bone marrow produces enormous numbers of cancerous cells that circulate in the blood. These abnormal cells do not function properly, so despite high numbers, the body’s defenses remain compromised.^[2]

In chronic myeloid leukemia, a specific genetic abnormality drives disease development. The BCR-ABL1 fusion gene, resulting from a chromosomal translocation, creates an abnormal protein that signals cells to divide continuously. This leads to massive overproduction of granulocytes and their immature forms. The disease can progress through different phases: a chronic phase with very high white blood cell counts but relatively few immature cells, an accelerated phase with increasing numbers of immature cells, and finally a blast phase that resembles acute leukemia.^[2]

Acute myeloid leukemia demonstrates how rapidly these cancers can develop. In this disease, immature cells called blasts multiply so quickly that they make up more than 20 percent of the cells in the bone marrow. The presence of Auer rods—distinctive rod-shaped structures inside the abnormal cells—is highly characteristic of myeloid leukemias. The rapid accumulation of blasts can lead to emergency situations like leukostasis, where excessive white blood cells clog small blood vessels and impair blood flow to organs.^[2]

Some haematological malignancies can cause tumor lysis syndrome, a dangerous condition where cancer cells break down so rapidly that they release their contents into the bloodstream faster than the kidneys can eliminate them. This creates imbalances in body chemistry that can damage organs. Similarly, disseminated intravascular coagulation can occur, where abnormal blood clotting and bleeding happen simultaneously throughout the body, creating a medical emergency.^[2]

The immune system becomes compromised in multiple ways. Not only does the shortage of normal white blood cells impair infection-fighting capability, but in myeloma, the failure to produce normal antibodies leaves gaps in the body’s defenses. The cancerous plasma cells make abnormal antibodies that do not work properly, while production of useful antibodies decreases.^[3]